A meta-analysis of 3 clinical trials (Checkmate 057, Keynote 010, and POPLAR) has also indicated that patients with NSCLC with EGFR mutations derive less benefits from anti–PD-1/PD-L1 treatment compared with patients without the mutation (8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.